Krazati (adagrasib) — Medica
Pancreatic adenocarcinoma
Initial criteria
- age ≥ 18 years
- KRAS G12C mutation-positive disease
- ONE of the following: (i) has locally advanced or metastatic disease AND previously treated with at least one systemic regimen OR (ii) has recurrent disease after resection
Approval duration
1 year